despit
first
report
year
ago
engraft
syndrom
es
remain
variabl
defin
complic
follow
hematopoiet
progenitor
cell
transplant
hpct
es
typic
character
occurr
new
noninfecti
fever
coincid
neutrophil
engraft
fever
may
associ
skin
rash
diarrhea
pulmonari
infiltr
hepat
dysfunct
although
case
es
selflimit
prolong
caus
sever
symptom
necessit
use
corticosteroid
underli
pathophysiolog
associ
es
remain
poorli
understood
base
lewi
rat
syngen
autolog
hpct
model
es
gener
believ
arisen
due
interplay
proinflammatori
cytokin
interleukin
il
tumor
necrosi
factor
tnf
interferon
ifn
associ
hematopoiet
recoveri
set
defici
reg
cell
mani
studi
examin
factor
predispos
patient
es
despit
es
associ
signific
transplantrel
morbid
pauciti
studi
examin
impact
health
resourc
util
set
determin
retrospect
studi
es
follow
autolog
hpct
affect
posttranspl
lengthofstay
ptlo
hospit
use
intraven
antimicrobi
addit
radiolog
examin
financi
cost
transplant
patient
demograph
clinic
data
diagnosi
treatment
histori
collect
electron
medic
record
cost
care
transplant
obtain
account
depart
medic
center
studi
approv
institut
review
board
new
york
medic
colleg
westchest
medic
center
transplant
carri
inpati
basi
high
effici
particul
air
filter
singl
room
use
autolog
peripher
blood
stem
cell
autolog
peripher
blood
stem
cell
mobil
use
gcsf
ae
plerixafor
mgkg
ae
chemotherapi
patient
receiv
gmcsf
start
day
prophylact
ciprofloxacin
fluconazol
acyclovir
absolut
neutrophil
count
drop
less
weekli
surveil
cytomegaloviru
detect
pcr
perform
patient
detect
threshold
iuml
iuml
defin
fever
oral
temperatur
f
fever
occur
day
day
consid
earlyonset
fever
new
fever
occur
day
day
discharg
consid
lateonset
fever
neutrophil
engraft
defin
attain
absolut
neutrophil
count
three
consecut
day
seventyf
consecut
patient
underw
peripher
blood
hpct
hematolog
malign
april
decemb
identifi
male
femal
median
age
year
rang
common
diagnosi
multipl
myeloma
follow
nonhodgkin
lymphoma
hodgkin
diseas
fortysix
patient
receiv
bortezomibcontain
regimen
prior
transplant
prepar
regimen
use
hpct
melphalan
mgm
rituxan
mgm
day
bcnu
mgm
day
etoposid
mgm
day
day
arac
mgm
day
day
melphalan
mgm
day
rbeam
beam
patient
divid
three
group
accord
occurr
fever
group
posttranspl
fever
group
fever
group
fever
statist
differ
found
among
three
group
age
sex
distribut
dose
cell
infus
underli
diagnosi
prior
use
bortezomib
transplant
prepar
regimen
dose
gmcsf
per
kg
bodi
weight
patient
earlyonset
fever
show
evid
neutrophil
engraft
within
h
develop
fever
fourteen
patient
develop
fever
peritranspl
period
sixtyon
patient
develop
posttranspl
fever
patient
develop
earlyonset
fever
lateonset
fever
microbi
organ
isol
patient
fever
toxigen
c
difficil
commonest
n
follow
vancomycinresist
enterococci
n
cytomegaloviru
n
viremia
coronaviru
n
epidermidi
n
staph
aureu
n
corynebacterium
jeikeium
n
like
epidermidi
contamin
bacteri
isol
obtain
blood
cultur
except
toxigen
c
difficil
detect
pcr
diarrheal
stool
differ
likelihood
posit
microbi
isol
two
group
patient
fever
two
group
patient
earlyonset
fever
patient
lateonset
fever
p
patient
develop
fever
significantli
longer
ptlo
hr
ci
p
compar
correspond
seah
h
lim
figur
effect
fever
engraft
syndrom
posttranspl
lengthofstay
hospit
patient
develop
fever
peritranspl
period
significantli
longer
posttranspl
lengthofstay
compar
develop
fever
b
impact
posttranspl
fever
lengthofstay
hospit
caus
primarili
develop
lateonset
fever
rather
earlyonset
fever
c
es
result
significantli
longer
posttranspl
lengthofstay
compar
develop
fever
correspond
ngml
followup
p
figur
report
evalu
serum
ferritin
followup
figur
c
report
perform
evalu
ge
hdxt
scanner
liver
heart
pancrea
followup
seven
patient
one
patient
exclud
analysi
due
lack
mri
followup
mean
valu
cardiac
millisecond
ms
baselin
followup
respect
p
three
patient
show
cardiac
iron
overload
baselin
pt
ms
pt
ms
disappear
followup
figur
mean
valu
liver
ms
baselin
followup
respect
p
five
patient
show
liver
iron
overload
baselin
moderatesever
mild
almost
disappear
followup
figur
mean
valu
pancrea
ms
baselin
followup
respect
p
none
patient
develop
iron
overload
liver
heart
alternatecombin
iron
chelat
therapi
none
patient
experienc
safeti
problem
previous
experienc
daili
monotherapi
either
dfo
dfx
dfp
alon
combin
alternatingcombin
iron
chelat
therapi
design
improv
patient
toler
achiev
desir
therapeut
efficaci
allow
continu
exposur
iron
chelat
effici
iron
clearanc
coverag
case
seri
daili
altern
regimen
dfp
dfx
effect
remov
iron
heart
liver
well
correspond
develop
posttranspl
fever
figur
median
ptlo
day
rang
ci
group
without
fever
day
rang
ci
group
fever
p
third
quartil
ptlo
group
without
fever
day
fever
day
p
differ
ptlo
two
group
predominantli
due
increas
ptlo
lateonset
fever
figur
statist
differ
ptlo
group
without
fever
group
earlyonset
fever
howev
median
ptlo
lateonset
fever
significantli
longer
compar
without
fever
day
vs
day
hr
ci
p
earli
onset
fever
vs
hr
ci
p
next
determin
impact
es
ptlo
first
use
follow
criteria
es
occurr
new
fever
associ
microbi
isol
infect
occur
hour
neutrophil
engraft
associ
skin
rash
pulmonari
infiltr
diarrhea
new
abnorm
liver
function
test
twenti
case
es
occur
cohort
patient
howev
includ
eight
patient
noninfecti
fever
whose
fever
probabl
due
es
even
though
fever
associ
rash
diarrhea
pulmonari
infiltr
abnorm
liver
function
test
incid
es
went
far
es
commonest
caus
new
fever
occur
day
respons
lateonset
fever
es
result
significantli
longer
ptlo
compar
without
fever
p
hr
ci
figur
median
ptlo
patient
es
day
ci
compar
day
ci
without
fever
p
conclus
es
occur
frequent
autolog
hpct
es
increas
transplantrel
morbid
also
resourc
util
identif
biomark
use
help
diagnos
es
highli
desir
patient
undergo
unnecessari
investig
addit
antimicrobi
therapi
consequ
result
longer
ptlo
higher
transplant
cost
elev
creactiv
protein
crp
found
associ
es
howev
crp
highli
nonspecif
also
elev
sepsi
complic
requir
aggress
antimicrobi
therapi
group
immunocompromis
patient
serum
procalcitonin
robust
biomark
sepsi
futur
studi
may
examin
combin
crp
procalcitonin
diagnosi
es
exclus
sepsi
patient
low
procalcitonin
accompani
elev
crp
confid
diagnos
es
spare
addit
investig
prolong
cours
intraven
antimicrobi
therapi
symptom
associ
es
http
daili
altern
deferasirox
deferipron
therapi
success
control
iron
accumul
untreat
transfusiondepend
thalassemia
patient
editor
chelat
therapi
treat
iron
overload
benefici
impact
prognosi
patient
transfusiondepend
thalassemia
tdt
three
differ
chelat
agent
current
avail
deferoxamin
dfo
given
subcutan
two
oral
agent
deferasirox
dfx
deferipron
dfp
patient
sever
iron
burden
monotherapi
adequ
effect
combin
dfo
dfp
well
establish
treatment
sever
iron
overload
heart
dysfunct
recent
combin
dfo
dfx
shown
safe
efficaci
treat
iron
overload
tdt
patient
nonrespond
standard
treatment
regimen
success
combin
therapi
dfx
dfp
report
previous
effect
reduc
iron
overload
superior
improv
cardiac
complianc
patient
satisfact
compar
deferoxaminedeferipron
combin
use
combin
therapi
address
intoler
monotherapi
common
practic
due
expect
patient
continu
exhibit
similar
wors
lack
toler
tdt
patient
toler
either
mono
combin
therapi
result
worsen
iron
overload
poor
prognosi
term
life
expect
median
adher
calcul
percentag
drug
taken
respect
one
issu
median
iron
intak
blood
transfus
mgyear
mean
followup
month
rang
mean
valu
serum
ferritin
baselin
